ADC Therapeutics SA

06/21/2021 | Press release | Distributed by Public on 06/21/2021 05:15

LOTIS-2 updated results demonstrate durable responses of ZYNLONTATM with median duration of response of 13.4 months in heavily pre-treated patients with relapsed or refractory[...]